RNAi for Therapeutic Applications: Technology and Market 2014-2024

治療応用のためのRNAi:技術および市場(2014-2024)

◆タイトル:RNAi for Therapeutic Applications: Technology and Market 2014-2024
◆商品コード:Visiongain-4052626
◆調査・発行会社:visiongain
◆発行日:2014年2月
◆ページ数:140
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single user licence(1名使用)GBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Dept Licence(部署内共有可)GBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site Licence(同一国内社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"治療応用のためのRNAi:技術および市場(2014-2024)"について調査・分析し、エグゼクティブサマリー、市場動向、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、研究開発パイプライン分析、専門家の見解、主要企業分析、結論などの情報をお届けいたします。

Potential of RNAi therapies – new analysis showing R&D, trends, and revenue prospects
Where are RNA interference based medicines going? For those treatments you can get new sales predictions and explore developments. You unlock that emerging medical industry. And you assess its results, trends, technologies, potentials, and opportunities.
Visiongain’s new report forecasts those revenues to 2024 at overall world market, product, and national level. Discover now what’s happening. You stay ahead in data, then, helping your influence. Hear about potential gains for companies pioneering those drugs.
Forecasts to 2024 and other analyses predict and explain the RNAi-based drug market
Why miss data you need? Why struggle to find it? Instead our report gives you revenue forecasts to 2024, also with historical data, growth rates, and market shares.
Also you investigate research and development, assessing its potential. The study also gives 59 tables, 26 charts, and interviews with two companies.
Prospects for that technology – analyses showing where the money lies
The new report shows the lucrative opportunities for ribonucleic acid interference (RNAi) technologies. And you discover forecasting for both optimistic and conservative scenarios. Those analyses predict how much money the pharma industry can earn.
See how that original analysis can benefit your reputation for commercial insight.
And the following sections explain what our investigation gives to help your research, analyses, and decisions.
Sales predictions for that world market and its products
What secrets influence RNAi medicine’s future? Once companies overcome technological challenges – gaining regulatory approval – patients will benefit. Discover in our report overall world revenue estimates to 2024 with discussions of trends and prospects.
Also you find individual revenue forecasts to 2024 for 11 therapeutic agents, including these:
• PF-655
• QPI-1007
• SYL040012
• ALN-RSV01
• ARC-520
• SPC3649 (Miravirsen).
There you assess advances and outlooks for those biopharmaceuticals. Hear where you could profit.
Where lie the best prospects? There you explore outlooks for sales, assessing where revenues and profits lie. Find data on gene silencing and its business potential.
For that biotechnology, our work also shows you geographical revenue predictions.
National markets – what outlooks to 2024 for RNAi drug revenues?
Advances in science, biotechnology and pharma expand possibilities of medicines harnessing RNAi interference. You gain feel for those technologies’ revenue prospects.
So our analyses give you individual revenue forecasts to 2024 for 11 national markets:
• United States (US)
• Japan
• EU leaders – Germany, France, the UK, Italy, and Spain (EU5)
• BRIC nations – Brazil, Russia, India, and China.
There you find regions with highest revenues, demand, and potential sales growth. Our work explains. You see international prospects.
Explore, too, how RNAi technology can benefit its developers, producers, marketers, and sellers. Our work shows you, also discussing technological progress and its meaning.
Developing products – discover trends, innovations, and progress
You also investigate R&D, finding technological and commercial possibilities. Our report discusses these advances and others:
• Short or small interfering RNA (siRNA)
• Expressed/DNA-directed RNAi (ddRNAi)
• Locked nucleic acid (LNA) and short hairpin RNA (shRNA), inc. viral vectors
• microRNA (miRNA) – natural gene expression regulators
• Novel drug delivery, including nanoparticle-based systems.
And it explores applications such as these:
• Ocular disorders, inc. age-related macular degeneration (AMD) and glaucoma
• Lung conditions, inc. respiratory syncytial virus (RSV) infection
• Infectious diseases, inc. hepatitis B and C virus (HBV and HCV) infections
• Kidney disease, inc. delayed graft function (DGF)
• Cancers – advantages in oncology.
Despite difficulties, pre-clinical and clinical developments there hold strength, variety, and promise. See what’s possible for big pharma and specialists in biological drugs (biologics).
And what events change that industry? Our work shows you, discussing trends and needs.
Developments, challenges, and effects influencing RNAi technologies
The report explains forces affecting that industry and market from 2014, including these:
• Reducing side effects, including adverse immune reactions
• Orphan drug designation for competitive advantages
• Personalised therapy, inc. targeting multiple cancer subtypes
• Prospects for combination therapy
• Strategic alliances, out-licensing technology, and contract manufacturing.
What happens next? There discover what the present and future hold. You examine what encourages and restrains players in that sector, and affects its results.
Analysis of companies leading that biotechnological field
From this decade, technological developments and needs of patients, doctors, and payers will encourage investments, medical advances, and sales of RNAi-based therapeutics.
And there you examine activities of many organisations, including these:
• Alnylam Pharmaceuticals
• Silence Therapeutics
• RXi Pharmaceuticals
• Quark Pharmaceuticals
• Santaris Pharma.
You find 119 organisations covered in the study. You also get interviews with authorities in that industry. Discover what participants do, say, and think.
Ways RNAi for Therapeutic Applications: Technology and Market 2014-2024 helps
In particular, our new investigation gives this knowledge to help your work:
• Revenues there to 2024 at world level and for 11 expected products – assess outlooks for approvals, production, marketing, and sales
• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia – explore developed and developing countries for future revenues
• Activities of companies in that biomedical field – investigate technologies, R&D pipelines, drug candidates, strategies, and prospects.
Data found nowhere else, helping your searches, analyses, and plans
Our study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. You explore commercial outlooks.
So with our findings you’re less likely to miss opportunity. Being free to choose, then, our study shows how you could save time and effort, also helping planning, decisions, and influence.
This new report is for everyone analysing emerging technologies in biopharma. For RNAi-based medicines you explore R&D trends, issues, and sales predictions. Avoid missing out, then – please order now.

【レポートの目次】

1. Executive Summary
1.1 RNAi Therapeutics: World Market Review
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Scope of this Report
2. Introduction to RNA Interference (RNAi): Technologies and Uses
2.1 Ribonucleic Acid (RNA): From DNA to Protein
2.2 RNA Interference (RNAi): A Natural Cellular Gene Silencing Process
2.2.1 The Endogenous Process of RNAi: The RNAi Machinery
2.2.2 RNAi Inducers: The Role of siRNA and miRNA
2.2.2.1 Short or Small Interfering RNA (siRNA): Application in Genetic Diseases
2.2.2.2 microRNA (miRNA): Natural Gene Expression Regulators
2.3 Timeline of RNAi: From Discovery to Human Trials in Six Years
2.4 The Therapeutic Potential of RNAi
2.4.1 Development of RNAi-Based Therapeutic Agents
2.4.1.1 The Delivery Approach: Exogenous Introduction of siRNA
2.4.1.2 The Expressed/DNA-directed RNAi (ddRNAi) Approach: A Stable Expression of RNAi Inducers
2.4.1.2.1 Short Hairpin RNA (shRNA): Employing Viral Vectors
2.4.2 Ribopharma AG: The First Company Specialising in RNAi Therapeutics
3. Leading Therapeutic Applications for RNAi
3.1 Therapeutic Fields Stimulating the RNAi Therapeutics Market to 2024
3.2 Ocular Disease – Many Needs Remain to Benefit Patients
3.2.1 Age-related Macular Degeneration (AMD)
3.2.2 Glaucoma – an Eye Disorder Benefiting from Technological Advances
3.3 Lung Diseases and Respiratory Disorders – Life Improving Treatments
3.3.1 Respiratory Syncytial Virus (RSV) Infection
3.4 Infectious Diseases – Protecting and Saving Lives Through Medical Progress
3.4.1 Hepatitis B and C Virus (HBV and HCV) Infections
3.5 Kidney Disease – Investigations to Treat the Excretory System
3.5.1 Delayed Graft Function (DGF)
3.6 Cancer – Prominent Field of Medicine Holds Great Scope for New Therapies
4. The RNAi Therapeutics Market 2014-2024
4.1 Scope and Limitations
4.2 The RNAi Therapeutics Market Forecast, 2014-2024
4.2.1 The RNAi Therapeutics Market: Industry Trends, 2014-2024
4.3 PF-655: Revenue Forecast, 2014-2024: Novel Mode of Action
4.4 QPI-1007: Revenue Forecast, 2014-2024: Unique Structure Reduces Risk of Off-Target Effects
4.5 SYL040012: Revenue Forecast, 2014-2024: Improved Efficacy Over Market-Leading Drug
4.6 ALN-RSV01: Revenue Forecast, 2014-2024: First RNAi to Demonstrate Therapeutic Efficacy
4.7 ARC-520: Revenue Forecast, 2014-2024: Rapid Reduction in Viral Antigen an Industry First
4.8 SPC3649 (Miravirsen): Revenue Forecast, 2014-2024: Revolutionary Treatment Targeting All Six HCV Subtypes?
4.9 QPI-1002: Revenue Forecast, 2014-2024: Orphan Designation Offers Market Exclusivity
4.10 FANG: Revenue Forecast, 2014-2024: Personalised Therapy Targeting Multiple Cancer Subtypes
4.11 ALN-VSP02: Revenue Forecast, 2014-2024: Dual-Target Action Adds to Therapeutic Potential
4.12 Atu027: Revenue Forecast, 2014-2024: High Prospects for Combination Therapy
4.13 CALAA-01: Revenue Forecast, 2014-2024: Demonstrating an RNAi Mechanism
5. Leading National RNAi Therapeutics Markets 2014-2024
5.1 Scope and Limitations
5.2 Leading National Markets: Revenue Forecasts, 2014-2024
5.2.1 The US: The Leading Market for RNAi Therapeutics
5.2.2 The EU5 RNAi Therapeutics Market: Pivotal Region for Companies
5.2.2.1 RNAi Therapeutics in the EU5 Submarkets, 2014-2024
5.2.3 Japanese RNAi Therapeutics Market, 2014-2024: Aging Population to Raise Demand for New Therapies
5.2.4 The Potential for RNAi Therapeutics in Emerging National Markets, 2014-2024
5.2.4.1 China Steps Up Efforts in RNAi Drug Development
5.2.4.2 India: Company Collaborations to Stimulate Interest in RNAi
5.2.4.3 Brazil: Economic Growth Helps Drug Discovery Efforts
5.2.4.4 Russia: Strong Market Environment Encourages R&D
6. Leading Companies in the RNAi Therapeutics Market, 2014
6.1 Alnylam Pharmaceuticals
6.1.1 Profile
6.1.2 A Strong Portfolio in the RNAi Field
6.1.3 Sales and Recent Performance, 2012
6.1.4 Entering Into Strategic Alliances to Generate Revenues
6.1.5 Contract Manufacturing of siRNAs by Tekmira Pharmaceuticals
6.1.6 Future Growth Strategy – Commercial Outlook
6.2 Silence Therapeutics
6.2.1 Profile
6.2.2 Lead Candidate Atu027 Expected to Complete Phase II in 2014
6.2.3 Multiple Delivery Technologies Offers Promise
6.2.4 Sales and Recent Performance, 2012
6.2.5 Partnerships for Silence Therapeutics’ RNAi Platform
6.3 RXi Pharmaceuticals
6.3.1 Profile
6.3.2 RXI-109: Lead RNAi Candidate Preventing Scar Formation
6.3.3 Sales and Recent Performance, 2012
6.4 Quark Pharmaceuticals
6.4.1 Profile
6.4.2 A Broad siRNA Clinical Pipeline
6.4.3 Quark Partnerships to Develop and Promote RNAi Therapies
6.5 Santaris Pharma
6.5.1 Profile
6.5.2 Locked Nucleic Acid (LNA) Platform: How Much Potential?
6.5.3 Sales and Recent Performance
6.5.4 Targeting Rare Genetic Diseases Through Shire plc Alliance
6.6 Tekmira Pharmaceuticals Corporation
6.6.1 Profile
6.6.2 Therapeutic R&D Pipeline Based on Novel Drug Delivery System
6.6.3 Sales and Recent Performance, 2012
6.6.4 Out-Licensing Technology Adds Extra Source of Revenue
6.7 Arrowhead Research Corporation
6.7.1 Profile
6.7.2 Company Focus: A Nanoparticle-Based Drug Delivery Platform
6.7.3 Sales and Recent Performance, 2012
6.7.4 Roche Acquisition Strengthens Company’s Market Position
6.8 Sylentis
6.8.1 Profile
6.8.2 The First Company in Spain to Conduct Clinical Trial of an RNAi Medicine
6.9 Gradalis
6.9.1 Overview
6.9.2 Company Pipeline: Vaccine based on shRNA in Clinical Trials
7. RNAi Therapeutics: Industry Trends 2014-2024
7.1 RNAi Therapeutics: Strengths and Weaknesses, 2014-2024
7.1.1 Therapeutic Targeting: A Highly Selective Treatment
7.1.2 Lower Therapeutic Dosages Will Attract Patients
7.1.3 Shorter Lead Identification Times: Providing Advantage over Other Approaches
7.1.4 Manufacturing Synthetic RNAs: Cost Effective and Easier Than for Other Biologics
7.1.5 The Big Challenge of Drug Delivery
7.1.5.1 Poor Cellular Uptake and Low Stability of siRNAs in Blood Serum
7.1.5.2 Systemic and Targeted Delivery of RNAi-based Drug Candidates
7.1.5.3 Industry’s Approach to Overcome the Introduction Challenges
7.1.6 Off-target Binding, Immune Response and Oversaturation Elevates Risk of Side Effects
7.2 RNAi Therapeutics: Opportunities and Threats, 2014-2024
7.2.1 Treating Multifactorial Diseases: A Revolutionary Therapeutic?
7.2.2 Competing Technologies
7.2.2.1 Antisense Technology: First-to-Market Advantage
7.2.2.2 Aptamers: Chemical Antibodies with Little Effect on Immune Activation
7.2.3 Regulatory Threats: Novel Class of Treatment May Lead to Prolonged or Delayed Approval Processes
7.2.4 Large Scale Production of RNAs: A Potential Threat to Commercialisation?
7.3 RNAi Therapeutics: STEP Analysis, 2014-2024
7.3.1 Social Forces
7.3.2 Technological Developments
7.3.3 Economic Pressures
7.3.4 Political Issues
8. Research Interviews
8.1 Respondent from Sylentis
8.1.1 Sylentis
8.1.1.1 The Current Status of the RNAi Therapeutics Market
8.1.1.2 Challenges in RNAi Drug Development
8.1.1.3 Sylentis’ RNAi Candidates and Platform Technology
8.1.1.4 The Future Outlook for RNAi Therapeutics
8.2 Dr Geert Cauwenbergh, RXi Pharmaceuticals
8.2.1 RXi Pharmaceuticals
8.2.1.1 The Potential of RNAi Therapeutics
8.2.1.2 Company History and OPKO Health Partnership
8.2.1.3 RXi’s Self-Delivering RNAi Technology
8.2.1.4 RX-109: RNAi Candidate for Post-Surgical Scarring
8.2.1.5 Prospects for the RNAi Therapeutics Market
9. Conclusions from Our Study
9.1 The RNAi Therapeutics Market in 2013
9.2 Outlook for the RNAi Therapeutics Market, 2014-2024
9.2.1 Regional Outlook for the Market, 2014-2024
9.3 Future Opportunities in RNAi Therapeutics
9.4 Challenges and Potential for Success Exist



List of Tables
Table 2.1 Advantages and Disadvantages of Using Chemically Modified Synthetic siRNAs
Table 2.2 Advantages of ddRNAi over siRNA, 2014
Table 4.1 RNAi Therapeutics in Clinical Development, 2013
Table 4.2 World RNAi Therapeutics Market: Revenue Forecasts ($m, AGR %, CAGR %) for Leading Drugs, 2013-2024: Optimistic Scenario
Table 4.3 World RNAi Therapeutics Market: Revenue Forecasts ($m, AGR %, CAGR %) for Leading Drugs, 2013-2024: Pessimistic Scenario
Table 4.4 The RNAi Therapeutics Market: Drivers and Restraints, 2014-2024
Table 4.5 PF-655: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Optimistic Scenario
Table 4.6 PF-655: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Pessimistic Scenario
Table 4.7 QPI-1007: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Optimistic Scenario
Table 4.8 QPI-1007: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Pessimistic Scenario
Table 4.9 SYL040012: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Optimistic Scenario
Table 4.10 SYL040012: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Pessimistic Scenario
Table 4.11 ALN-RSV01: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Optimistic Scenario
Table 4.12 ALN-RSV01: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Pessimistic Scenario
Table 4.13 ARC-520: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Optimistic Scenario
Table 4.14 ARC-520: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Pessimistic Scenario
Table 4.15 SPC3649 (Miravirsen): Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Optimistic Scenario
Table 4.16 SPC3649 (Miravirsen): Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Pessimistic Scenario
Table 4.17 QPI-1002: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Optimistic Scenario
Table 4.18 QPI-1002: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Pessimistic Scenario
Table 4.19 FANG: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Optimistic Scenario
Table 4.20 FANG: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Pessimistic Scenario
Table 4.21 ALN-VSP02: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Optimistic Scenario
Table 4.22 ALN-VSP02: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Pessimistic Scenario
Table 4.23 Atu027: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Optimistic Scenario
Table 4.24 Atu027: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Pessimistic Scenario
Table 4.25 CALAA-01: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Optimistic Scenario
Table 4.26 CALAA-01: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Pessimistic Scenario
Table 5.1 The RNAi Therapeutics Market: Revenue Forecasts ($m, AGR %, CAGR %) by Region, 2013-2024: Optimistic Scenario
Table 5.2 The RNAi Therapeutics Market: Revenue Forecasts ($m, AGR %, CAGR %) by Region, 2013-2024: Pessimistic Scenario
Table 5.3 The US RNAi Therapeutics Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Optimistic Scenario
Table 5.4 The US RNAi Therapeutics Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Pessimistic Scenario
Table 5.5 The EU5 RNAi Therapeutics Market: Revenue Forecasts ($m, AGR %, CAGR %) by Country, 2013-2024: Optimistic Scenario
Table 5.6 The EU5 RNAi Therapeutics Market: Revenue Forecasts ($m, AGR %, CAGR %) by Country, 2013-2024: Pessimistic Scenario
Table 5.7 The Japanese RNAi Therapeutics Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Optimistic Scenario
Table 5.8 The Japanese RNAi Therapeutics Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024: Pessimistic Scenario
Table 5.9 BRIC Nations' RNAi Therapeutics Markets: Revenue Forecasts ($m, AGR %, CAGR %) by Country, 2013-2024: Optimistic Scenario
Table 5.10 BRIC Nations' RNAi Therapeutics Markets: Revenue Forecasts ($m, AGR %, CAGR %) by Country, 2013-2024: Pessimistic Scenario
Table 6.1 Alnylam Pharmaceuticals' RNAi Drug Pipeline, 2013
Table 6.2: Alnylam Pharmaceuticals: Revenue from Collaborations ($,'000), 2011 and 2012
Table 6.3 Silence Therapeutics' RNAi Drug Pipeline, 2013
Table 6.4 Silence Therapeutics: Revenues ($m) by Region, 2011 & 2012
Table 6.5 Quark Pharmaceuticals' RNAi Drug Pipeline, 2013
Table 6.6 Santaris' RNAi Drug Pipeline, 2013
Table 6.7 Santaris Pharma: Revenue ($m), 2010 and 2011
Table 6.8 Tekmira Pharmaceuticals' RNAi Drug Pipeline, 2013
Table 6.9 Tekmira Pharmaceuticals: Revenue ($m), 2011 and 2012
Table 6.10 Arrowhead Research Corporations' RNAi Drug Pipeline, 2013
Table 6.11 Arrowhead Research Corporation: Revenue ($m, CAGR %), 2009-2013
Table 6.12 Sylentis' RNAi Drug Pipeline, 2013
Table 6.13 Gradalis' RNAi Vaccine and Drug Pipeline, 2013
Table 7.1 The RNAi Therapeutics Market: Strengths and Weaknesses, 2014-2024
Table 7.2 Leading Contract Manufacturing Organisations Developing Oligonucleotide APIs, 2013
Table 7.3 Advantages of Local Delivery Over Systemic Delivery, 2014
Table 7.4 Leading Companies Developing RNAi Delivery Systems and Technologies, 2013
Table 7.5 The RNAi Therapeutics Market: Opportunities and Threats, 2014-2024
Table 7.6 Leading Companies Developing Antisense Drugs, 2013
Table 7.7 Leading Companies Developing Aptamer Drugs, 2013
Table 9.1 World RNAi Therapeutics Market: Overall Revenue Forecasts ($m, Three-Year Growth %, CAGR %) for Leading Drugs, 2012, 2015, 2018, 2021 and 2024
List of Figures
Figure 2.1 The Basic Process of RNAi
Figure 2.2 Model of RNA Interference: Cleavage Dependent Mechanism
Figure 4.1 World RNAi Therapeutics Market: Revenue Forecasts ($m), 2013-2024: Optimistic and Pessimistic Scenario
Figure 4.2 PF-655: Revenue Forecast ($m), 2013-2024: Optimistic and Pessimistic Scenarios
Figure 4.3 QPI-1007: Revenue Forecast ($m), 2013-2024: Optimistic and Pessimistic Scenarios
Figure 4.4 SYL040012: Revenue Forecast ($m), 2013-2024: Optimistic and Pessimistic Scenarios
Figure 4.5 ALN-RSV01: Revenue Forecast ($m), 2013-2024: Optimistic and Pessimistic Scenarios
Figure 4.6 ARC-520: Revenue Forecast ($m), 2013-2024: Optimistic and Pessimistic Scenarios
Figure 4.7 SPC3649 (Miravirsen): Revenue Forecast ($m), 2013-2024: Optimistic and Pessimistic Scenarios
Figure 4.8 QPI-1002: Revenue Forecast ($m), 2013-2024: Optimistic and Pessimistic Scenarios
Figure 4.9 FANG: Revenue Forecast ($m), 2013-2024: Optimistic and Pessimistic Scenarios
Figure 4.10 ALN-VSP02: Revenue Forecast ($m), 2013-2024: Optimistic and Pessimistic Scenarios
Figure 4.11 Atu027: Revenue Forecast ($m), 2013-2024: Optimistic and Pessimistic Scenarios
Figure 4.12 CALAA-01: Revenue Forecast ($m), 2013-2024: Optimistic and Pessimistic Scenarios
Figure 5.1 The US RNAi Therapeutics Market: Revenue Forecast ($m), 2013-2024: Optimistic and Pessimistic Scenarios
Figure 5.2 The EU5 RNAi Therapeutics Market: Revenue Forecast ($m), 2013-2024: Optimistic and Pessimistic Scenarios
Figure 5.3 The EU5 RNAi Therapeutics Market: Revenue Forecasts ($m) by Country, 2013-2024: Optimistic Scenarios
Figure 5.4 The EU5 RNAi Therapeutics Market: Revenue Forecasts ($m) by Country, 2013-2024: Pessimistic Scenarios
Figure 5.5 The Japanese RNAi Therapeutics Market: Revenue Forecast ($m), 2013-2024: Optimistic and Pessimistic Scenarios
Figure 5.6 The BRIC RNAi Therapeutics Market: Revenue Forecasts ($m) by Country, 2013-2024: Optimistic Scenarios
Figure 5.7 The BRIC RNAi Therapeutics Market: Revenue Forecasts ($m) by Country, 2013-2024: Pessimistic Scenarios
Figure 6.1 Alnylam Pharmaceuticals: Revenue Share (%) from Collaborations, 2012
Figure 6.2 Silence Therapeutics: Revenue Share (%) by Region, 2012
Figure 6.3 Santaris Pharma: Revenue ($m), 2010 and 2011
Figure 6.4 Arrowhead Research Corporation: Revenue ($m), 2009-2013
Figure 9.1 World RNAi Therapeutics Market: Overall Revenue Forecasts ($m), 2012, 2015, 2018, 2021 and 2024: Optimistic and Pessimistic Scenarios


【掲載企業】

Acuity Pharmaceuticals
Aegera Therapeutics
Agilent Technologies
Alcon
Allele Biotechnology
Allergan
Alnylam Pharmaceuticals
Altogen Labs
Antisense Therapeutics
Antisoma Research
Archemix Corporation
ArmaGen Technologies
Arrowhead Research Corporation
Ascletis Pharmaceuticals
AstraZeneca
Atlantic Pharmaceuticals
Atugen AG
Avecia OligoMedicines
AVI BioPharma
Bayer
Bio Synthesis
Biocon
Biogen Idec
Biomatik Corporation
Biomics Biotechnologies
Bionexus
BioSpring
Bristol-Myers Squibb
Calando Pharmaceuticals
Carnegie Institution for Science
Chinese University of Hong Kong
Cubist Pharmaceuticals
Dainippon Sumitomo Pharma
Dharmacon RNAi Technologies
Eleos
Eli Lilly
Enzo Therapeutics
Enzon Pharmaceuticals
Eurofins MWG-Biotech
Eurogentec
European Commission
European Medicines Agency (EMA)
European Union (EU)
Expression Genetics
Eyetech Pharmaceuticals
EZBiolab
Food and Drug Administration (US FDA)
Gene Link
Gene Signal International
GeneCare Research Institute
GeneDesign
Genentech
Genta Incorporated
Genzyme
Girindus America
Gradalis
GlaxoSmithKline (GSK)
Halo-Bio RNAi Therapeutics
Integrated DNA Technologies
Intradigm Corporation
Invitrogen
Isarna Therapeutics
ISIS Pharmaceuticals
Kyowa Hakko Kirin
Life Technologies
Lorus Therapeutics
Marina Biotech
Mary Crowley Cancer Research Centre
Max Planck Institute
MedImmune
Medtronic
Merck & Co.
Merz Pharmaceuticals
Nitto Denko Corporation
Novartis
NovaRx Corporation
Novosom
Noxxon Pharma
Ohio State University (OSU)
Oligoengine
OncoGenex Technologies
Ophthotech Corporation
OPKO Health
OSI Pharmaceuticals
Pfizer
Protiva Biotherapeutics
Qiagen
Quark Biotech
Quark Pharmaceuticals
Regado Biosciences
Regeneron Pharmaceuticals
Ribopharma AG
RiboTask
RXi Pharmaceuticals
Roche
SABiosciences
Samyang Corporation
Santaris Pharma
Sanofi
Shire
Sigma Aldrich
Silence Therapeutics
Sirnaomics
Sirna Therapeutics
Spanish Society for Glaucoma
Solvay Group
Suzhou Ribo Life Sciences
Sylentis
Talon Pharmaceuticals
Takeda
Targeted Genetics Corporation
Tekmira Pharmaceuticals
Teva Pharmaceuticals
The Medicines Company
Thermo Scientific
Traversa Therapeutics
University of Bayreuth
University of Massachusetts Medical School
VIRxSYS
World Health Organization (WHO)
Zeltia Group


★調査レポート[治療応用のためのRNAi:技術および市場(2014-2024)] ( RNAi for Therapeutic Applications: Technology and Market 2014-2024 / Visiongain-4052626) 販売に関する免責事項
[治療応用のためのRNAi:技術および市場(2014-2024)] ( RNAi for Therapeutic Applications: Technology and Market 2014-2024 / Visiongain-4052626) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆